DK1283839T3 - Adenosin A2a-receptorantagonister - Google Patents

Adenosin A2a-receptorantagonister

Info

Publication number
DK1283839T3
DK1283839T3 DK01945991T DK01945991T DK1283839T3 DK 1283839 T3 DK1283839 T3 DK 1283839T3 DK 01945991 T DK01945991 T DK 01945991T DK 01945991 T DK01945991 T DK 01945991T DK 1283839 T3 DK1283839 T3 DK 1283839T3
Authority
DK
Denmark
Prior art keywords
adenosine
receptor antagonists
antagonists
receptor
Prior art date
Application number
DK01945991T
Other languages
Danish (da)
English (en)
Inventor
Bernard R Neustadt
William J Greenlee
Deen Tulshian
Lisa S Silverman
Yan Xia
Craig D Boyle
Samuel Chackalamannil
Neil A Lindo
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK1283839T3 publication Critical patent/DK1283839T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK01945991T 2000-05-26 2001-05-24 Adenosin A2a-receptorantagonister DK1283839T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20714300P 2000-05-26 2000-05-26
EP01945991A EP1283839B1 (en) 2000-05-26 2001-05-24 Adenosine a2a receptor antagonists
PCT/US2001/016954 WO2001092264A1 (en) 2000-05-26 2001-05-24 Adenosine a2a receptor antagonists

Publications (1)

Publication Number Publication Date
DK1283839T3 true DK1283839T3 (da) 2005-07-25

Family

ID=22769372

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01945991T DK1283839T3 (da) 2000-05-26 2001-05-24 Adenosin A2a-receptorantagonister

Country Status (31)

Country Link
US (4) US6630475B2 (zh)
EP (1) EP1283839B1 (zh)
JP (3) JP4574112B2 (zh)
KR (1) KR100520907B1 (zh)
CN (2) CN1247588C (zh)
AR (1) AR028621A1 (zh)
AT (1) ATE293627T1 (zh)
AU (2) AU2001268089C1 (zh)
BR (1) BRPI0111015B8 (zh)
CA (1) CA2410237C (zh)
CZ (1) CZ303790B6 (zh)
DE (1) DE60110219T2 (zh)
DK (1) DK1283839T3 (zh)
EC (1) ECSP024364A (zh)
ES (1) ES2237576T3 (zh)
HK (1) HK1049007B (zh)
HU (1) HU230420B1 (zh)
IL (3) IL152726A0 (zh)
MX (1) MXPA02011625A (zh)
MY (1) MY132006A (zh)
NO (1) NO325008B1 (zh)
NZ (1) NZ522326A (zh)
PE (1) PE20020062A1 (zh)
PL (1) PL218764B1 (zh)
PT (1) PT1283839E (zh)
RU (1) RU2315053C2 (zh)
SI (1) SI1283839T1 (zh)
SK (1) SK287748B6 (zh)
TW (1) TWI288137B (zh)
WO (1) WO2001092264A1 (zh)
ZA (1) ZA200208898B (zh)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100520907B1 (ko) * 2000-05-26 2005-10-11 쉐링 코포레이션 아데노신 Ａ2ａ수용체 길항제
MXPA04002389A (es) * 2001-09-13 2004-05-31 Schering Corp Combinacion de un antagonista del receptor de adenosian a2a y un antidepresivo o ansiolitico.
CN100421663C (zh) 2001-10-15 2008-10-01 先灵公司 咪唑并（4,3－E）,1,2,4－三唑并（1,5－C）嘧啶类化合物作为腺苷A2a受体拮抗剂
FR2832405B1 (fr) * 2001-11-19 2004-12-10 Sanofi Synthelabo Tetrahydropyridyl-alkyl-heterocycles azotes, procede pour leur preparation et compositions pharmaceutiques les contenant
PE20030739A1 (es) 2001-11-30 2003-08-28 Schering Corp Antagonistas del receptor de adenosina a2a
IL161716A0 (en) * 2001-11-30 2004-09-27 Schering Corp ADENOSINE A2a RECEPTOR ANTAGONISTS
AU2002352933A1 (en) 2001-11-30 2003-06-17 Schering Corporation [1,2,4]-triazole bicylic adenosine A2a receptor antagonists
HUE043353T2 (hu) 2002-01-28 2019-08-28 Kyowa Hakko Kogyo Kk A2A receptor antagonisták mozgás zavarok kezelésében történõ alkalmazásra
KR20040111324A (ko) 2002-05-30 2004-12-31 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 트리사이클릭 파이라졸로트리아졸로피리미딘 링 구조를지닌 약제학적 활성화합물 및 사용 방법
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
EP2269596A3 (en) * 2002-12-19 2011-09-14 Schering Corporation Use of adenosine A2a receptor antagonists for the treatment of extrapyramidal syndrome and other movement disorders
WO2004092172A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosin e receptor antagonists
US6897217B2 (en) 2003-04-23 2005-05-24 Schering Corporation 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
AU2004244906A1 (en) * 2003-06-10 2004-12-16 Kyowa Hakko Kirin Co., Ltd. A method of treating an anxiety disorder
JP2006527212A (ja) * 2003-06-12 2006-11-30 ノボ　ノルディスク　アクティーゼルスカブ ホルモン感受性リパーゼの阻害剤として使用するための、置換ピペラジンカルバメート
CA2541989C (en) * 2003-10-24 2013-10-01 Exelixis, Inc. P70s6 kinase modulators and method of use
PT1678182E (pt) * 2003-10-28 2007-04-30 Schering Corp Processo para preparar 5-amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pirimidinas
ATE377599T1 (de) * 2003-12-01 2007-11-15 Schering Corp Verfahren zur herstellung von substituierten 5- aminopyrazolo(4,3-e)-1,2,4-triazolo(1,5- c)pyrimidinen
US20060009504A1 (en) * 2003-12-19 2006-01-12 Schering Corporation Pharmaceutical compositions
ES2342082T3 (es) * 2004-04-21 2010-07-01 Schering Corporation Antagonistas de receptores a2a de adenosina de pirazolo(4,3-e)-1,2,4-triazolo(1,5-c)pirimidina.
US7851478B2 (en) * 2005-06-07 2010-12-14 Kyowa Hakko Kirin Co., Ltd. Agent for preventing and/or treating movement disorder
EP1934227B1 (en) * 2005-09-19 2011-12-21 Schering Corporation 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
AR056080A1 (es) 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
WO2008008398A2 (en) * 2006-07-14 2008-01-17 Shionogi & Co., Ltd. Oxime compounds and the use thereof
TW200840566A (en) * 2006-12-22 2008-10-16 Esteve Labor Dr Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments
US7723343B2 (en) 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
WO2009114533A2 (en) 2008-03-10 2009-09-17 Cornell University Modulation of blood brain barrier permeability
US8669260B2 (en) * 2008-02-29 2014-03-11 Albert Einstein College Of Medicine Of Yeshiva University Ketoconazole-derivative antagonist of human pregnane X receptor and uses thereof
JP2011513417A (ja) 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
TWI473614B (zh) 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
EP2564871B1 (en) * 2008-07-23 2017-11-15 Kyowa Hakko Kirin Co., Ltd. Therapeutic Agent for Migraine
US20100093702A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2010078430A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
MX2011007678A (es) 2009-01-20 2011-08-08 Schering Corp Metodos para aliviar o tratar señales y/o sintomas asociados con enfermedad de parkinson de moderada a severa.
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
WO2010103547A2 (en) 2009-03-13 2010-09-16 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
US8343961B2 (en) 2009-03-31 2013-01-01 Arqule, Inc. Substituted heterocyclic compounds
US8537177B2 (en) 2009-06-15 2013-09-17 Marvell World Trade Ltd. System and methods for gamut bounded saturation adaptive color enhancement
WO2011017299A2 (en) 2009-08-07 2011-02-10 Schering Corporation PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE
US8859555B2 (en) 2009-09-25 2014-10-14 Oryzon Genomics S.A. Lysine Specific Demethylase-1 inhibitors and their use
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
RS55348B1 (sr) 2010-04-19 2017-03-31 Oryzon Gnomics S A Inhibitori lizin specifične demetilaze-1 i njihova upotreba
EP2598482B1 (en) 2010-07-29 2018-04-04 Oryzon Genomics, S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
WO2012038980A2 (en) * 2010-09-24 2012-03-29 Advinus Therapeutics Limited Fused tricyclic compounds as adenosine receptor antagonist
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
WO2012107498A1 (en) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative disorders
WO2012129381A1 (en) * 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
WO2012127472A1 (en) * 2011-03-22 2012-09-27 Mapi Pharma Ltd. Process and intermediates for the preparation of preladenant and related compounds
WO2013024474A1 (en) * 2011-08-18 2013-02-21 Mapi Phrarma Ltd. Polymorphs of preladenant
IN2014CN03337A (zh) 2011-10-20 2015-07-03 Oryzon Genomics Sa
MX356344B (es) 2011-10-20 2018-05-23 Oryzon Genomics Sa Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1.
WO2014071512A1 (en) * 2012-11-06 2014-05-15 Universite Laval Combination therapy and methods for the treatment of respiratory diseases
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
EP3220910B1 (en) 2014-11-18 2020-01-15 Merck Sharp & Dohme Corp. Aminopyrazine compounds with a2a antagonist properties
EP3253390B1 (en) 2015-02-06 2022-04-13 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as a2a antagonist
WO2016200717A1 (en) 2015-06-11 2016-12-15 Merck Sharp & Dohme Corp. Aminopyrazine compounds with a2a antagonist properties
WO2017008205A1 (en) 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
MX2019011743A (es) * 2017-03-30 2020-01-20 Iteos Therapeutics Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres.
TWI801372B (zh) * 2017-03-30 2023-05-11 比利時商艾特歐斯比利時有限公司 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法
EP3723754A4 (en) 2017-12-13 2021-05-19 Merck Sharp & Dohme Corp. IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
US11407758B2 (en) 2018-01-04 2022-08-09 Impetis Biosciences Ltd. Tricyclic compounds, compositions and medicinal applications thereof
IL303087B1 (en) 2018-02-27 2024-08-01 Incyte Corp Midazopyrimidines and triazolopyrimidines as A2A /A2B inhibitors
CN108276345A (zh) * 2018-03-22 2018-07-13 重庆奥舍生物化工有限公司 一种药物中间体嘧啶-5-甲醛的制备方法
WO2019196803A1 (en) * 2018-04-08 2019-10-17 Beigene, Ltd. Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
CN108864114B (zh) * 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂
CN113166153A (zh) 2018-07-05 2021-07-23 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
CN110742893B (zh) * 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法
JP7241871B2 (ja) 2018-11-30 2023-03-17 メルク・シャープ・アンド・ドーム・エルエルシー アデノシン受容体拮抗薬としての９－置換されたアミノトリアゾロキナゾリン誘導体、医薬組成物及びそれらの使用
US11459329B2 (en) 2018-12-20 2022-10-04 Incyte Corporation Imidazopyridazine and imidazopyridine compounds and uses thereof
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US20220235056A1 (en) * 2019-05-03 2022-07-28 Nektar Therapeutics Adenosine 2 receptor antagonists
DE102019116986A1 (de) 2019-06-24 2020-12-24 Helmholtz-Zentrum Dresden-Rossendorf E. V. Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
US20230024108A1 (en) * 2019-07-17 2023-01-26 Teon Therapeutics, Inc. Adenosine a2a receptor antagonists
CN112592354B (zh) 2019-07-30 2022-05-27 厦门宝太生物科技股份有限公司 一种异噁唑并嘧啶类杂环化合物的制备方法
CN112592346B (zh) 2019-07-30 2022-04-26 厦门宝太生物科技股份有限公司 一种a2a和/或a2b抑制剂中间体的制备方法
CN111072675A (zh) * 2019-12-12 2020-04-28 广东东阳光药业有限公司 含氮稠合三环衍生物及其用途
JP7431665B2 (ja) 2020-05-20 2024-02-15 Ykk Ap株式会社 接合構造および建具
CN113773327B (zh) * 2021-09-13 2022-07-15 八叶草健康产业研究院(厦门)有限公司 一种吡唑并嘧啶并三唑环类化合物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU466232A1 (ru) * 1973-05-23 1975-04-05 Киевский Ордена Ленина Государственный Университет Им.Т.Г.Шевченко Споссоб получени конденсированных пиримидо- -триазиниевых соединений с мостиковыми атомами азота
EP0217748B1 (en) 1985-09-30 1991-02-06 Ciba-Geigy Ag 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof
SU1739850A3 (ru) * 1987-08-31 1992-06-07 Такеда Кемикал Индастриз, Лтд (Фирма) Способ получени конденсированных производных пиразоло[3,4- @ ]пиримидина
IT1264901B1 (it) * 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
US5565460A (en) 1993-07-27 1996-10-15 Kyowa Hakko Koygo Co., Ltd. Therapeutic purine agents for parkinson's disease
IT1277392B1 (it) * 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) * 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
KR100520907B1 (ko) * 2000-05-26 2005-10-11 쉐링 코포레이션 아데노신 Ａ2ａ수용체 길항제
IL161716A0 (en) * 2001-11-30 2004-09-27 Schering Corp ADENOSINE A2a RECEPTOR ANTAGONISTS
EP2269596A3 (en) * 2002-12-19 2011-09-14 Schering Corporation Use of adenosine A2a receptor antagonists for the treatment of extrapyramidal syndrome and other movement disorders
PT1678182E (pt) * 2003-10-28 2007-04-30 Schering Corp Processo para preparar 5-amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pirimidinas
ATE377599T1 (de) * 2003-12-01 2007-11-15 Schering Corp Verfahren zur herstellung von substituierten 5- aminopyrazolo(4,3-e)-1,2,4-triazolo(1,5- c)pyrimidinen
ES2342082T3 (es) * 2004-04-21 2010-07-01 Schering Corporation Antagonistas de receptores a2a de adenosina de pirazolo(4,3-e)-1,2,4-triazolo(1,5-c)pirimidina.
EP1934227B1 (en) * 2005-09-19 2011-12-21 Schering Corporation 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
PT1283839E (pt) 2005-08-31
CN1451007A (zh) 2003-10-22
AU2001268089B2 (en) 2005-04-28
BR0111015A (pt) 2005-01-11
PE20020062A1 (es) 2002-02-02
AR028621A1 (es) 2003-05-14
USRE44205E1 (en) 2013-05-07
US20040023997A1 (en) 2004-02-05
HK1049007A1 (en) 2003-04-25
US20020099061A1 (en) 2002-07-25
JP4938348B2 (ja) 2012-05-23
EP1283839B1 (en) 2005-04-20
HUP0600239A2 (en) 2006-07-28
IL220174A (en) 2015-07-30
MY132006A (en) 2007-09-28
CZ303790B6 (cs) 2013-05-09
US6630475B2 (en) 2003-10-07
US20050026932A1 (en) 2005-02-03
SI1283839T1 (zh) 2005-08-31
RU2315053C2 (ru) 2008-01-20
WO2001092264A1 (en) 2001-12-06
BRPI0111015B8 (pt) 2021-05-25
DE60110219T2 (de) 2006-03-09
AU2001268089C1 (en) 2006-04-13
ATE293627T1 (de) 2005-05-15
PL218764B1 (pl) 2015-01-30
CN100384847C (zh) 2008-04-30
SK287748B6 (sk) 2011-08-04
TWI288137B (en) 2007-10-11
JP4574112B2 (ja) 2010-11-04
CZ20023886A3 (cs) 2003-02-12
IL220174A0 (en) 2012-07-31
NZ522326A (en) 2006-03-31
KR100520907B1 (ko) 2005-10-11
JP2003535094A (ja) 2003-11-25
JP2007145875A (ja) 2007-06-14
ES2237576T3 (es) 2005-08-01
JP2006219497A (ja) 2006-08-24
AU6808901A (en) 2001-12-11
CA2410237C (en) 2008-01-08
IL152726A (en) 2012-07-31
HU230420B1 (hu) 2016-05-30
DE60110219D1 (de) 2005-05-25
ZA200208898B (en) 2004-03-01
BRPI0111015B1 (pt) 2017-11-07
CN1247588C (zh) 2006-03-29
EP1283839A1 (en) 2003-02-19
NO325008B1 (no) 2008-01-14
ECSP024364A (es) 2003-03-31
KR20030003746A (ko) 2003-01-10
CA2410237A1 (en) 2001-12-06
PL360472A1 (en) 2004-09-06
IL152726A0 (en) 2003-06-24
MXPA02011625A (es) 2003-03-27
NO20025651L (no) 2003-01-23
NO20025651D0 (no) 2002-11-25
US6897216B2 (en) 2005-05-24
SK16712002A3 (sk) 2003-08-05
HUP0600239A3 (en) 2008-06-30
HK1049007B (zh) 2005-09-16
US7067655B2 (en) 2006-06-27
CN1800186A (zh) 2006-07-12

Similar Documents

Publication Publication Date Title
ATE293627T1 (de) Adenosin a2a rezeptor antagonisten
ATE453647T1 (de) Adenosin a2a rezeptor antagonisten
ATE317844T1 (de) Adenosine a2a receptor antagonisten
DE60219196D1 (de) BICYCLISCHE Ä1,2,4ö-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN
DE60007127D1 (de) N-pyrazol a2a rezeptor agonisten
ATE240341T1 (de) C-pyrazol a2a rezeptor agonisten
IS5706A (is) Adenosín A3 viðtakastillar
HUP0401925A3 (en) A2b adenosine receptor antagonists
DE60110391D1 (de) Adenosin-rezeptor modulatoren
PT1192170E (pt) Agonistas de receptor a2a de propargilfenileter
NO20020979L (no) Selektive A2B-adenosinreseptorantagonister
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
ATE394402T1 (de) Kondensierte purinderivate als a1- adenosinrezeptorantagonisten
ATE281456T1 (de) Aminotriazolopyridinderivate als adenosinrezeptorliganden
DE60220713D1 (de) Ribofuranosyluronamid Derivate als Kristall; ein menschlicher Adenosin A2A Rezeptor Agonsit
SI1444233T1 (sl) Antagonisti adenozinskega receptorja A2B
TH109999B (th) นิวคลีโอไซด์